Skip to main content

Animations

The Parkinson's Precision Medicine Initiative is our landmark study launched in 2010 to deepen knowledge of Parkinson's and to better understand its onset and progression to speed the development of new treatments. Learn the latest news from the study here.


  • Samples in the lab

    PPMI Dispatch: Landmark Study Opens Enrollment While Analysis Points to Potential Blood Test for Parkinson’s

    Some sites are enrolling new volunteers into our Parkinson’s Progression Markers Initiative, and scientists are getting closer to a blood test to track disease progression.
    Learn more Save for later


  • Two researchers in lab looking at samples

    PPMI Dispatch: Closer to Predicting Disease Progression and Symptoms

    Findings from our Parkinson’s Progression Markers Initiative study point to potential ways to measure progression and predict disease.
    Learn more Save for later

  • Research Testing

    PPMI Dispatch: Identifying Differences in Disease Profiles and Impact on Quality of Life

    Findings from the Parkinson’s Progression Markers Initiative show differences in symptoms among participants with genetic mutations and compare automatic functions over time with quality of life.
    Learn more Save for later

  • Scientist in Lab

    PPMI Dispatch: Streamlined Data, Genetic Indicators and Cognitive Decline Predictors

    Data from the Parkinson’s Progression Markers Initiative has been downloaded more than 5 million times. View recent findings and updates from the study.
    Learn more Save for later

  • Theresa Lin, Sarah Simon, Katherine Leaver, Sonya Elango, Susan Bressman, Deborah Raymond, Rachel Saunders-Pullman

    Research Community Thanks Parkinson’s Study Participants

    Research volunteers advance understanding and treatment of Parkinson’s disease. Foundation staff and partners recently thanked local participants.
    Learn more Save for later

We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.